Effect of arundic acid on serum S-100β in ischemic stroke

L. Creed Pettigrew; Scott E. Kasner; Mark Gorman; Richard P. Atkinson; Yosuke Funakoshi; Hideyasu Ishibashi

doi:10.1016/j.jns.2006.09.002

Effect of arundic acid on serum S-100β in ischemic stroke

L. Creed Pettigrew, Scott E. Kasner, Mark Gorman, Richard P. Atkinson, Yosuke Funakoshi, Hideyasu Ishibashi

Research output: Contribution to journal › Article › peer-review

20 Scopus citations

Abstract

We prospectively examined the effect of arundic acid (AA; ONO-2506) on S-100β, an astrocyte-derived protein, in a phase I acute stroke study. Subjects with acute ischemic stroke were randomized to daily infusion of AA or placebo for 7 days. Serum S-100β levels were assayed pre-infusion on Days 1-7 and post-infusion on Days 1, 3, and 7, and correlated with National Institutes of Health Stroke Scale (NIHSS). Samples were obtained from 86 subjects (46 AA, 40 placebo). Increase in S-100β protein level from baseline was less in the AA cohort than in the placebo cohort at 7 (p = 0.0471; t-test) and 12 (p = 0.0095)-hours post-infusion on Day 3. Baseline NIHSS correlated with maximal S-100β levels between Days 1 and 3 in the AA (r = 0.51; p = 0.0003) and placebo (r = 0.41; p = 0.0084) cohorts and in the pooled aggregate (n = 86; r = 0.46; p < 0.0001). The same correlations were observed between Day 10 NIHSS and Day 1-3 maximum serum S-100β levels. Treatment with AA was associated with lower serum levels of S-100β after acute ischemic stroke. Our results showing correlation between S-100β and NIHSS indicate that this protein is a clinically relevant marker of neurological deficit in acute stroke.

Original language	English
Pages (from-to)	57-61
Number of pages	5
Journal	Journal of the Neurological Sciences
Volume	251
Issue number	1-2
DOIs	https://doi.org/10.1016/j.jns.2006.09.002
State	Published - Dec 21 2006

Bibliographical note

Funding Information:
Financial support for this work was provided by Ono Pharma USA Inc., of Lawrenceville, NJ, as a grant awarded to each participating center and by NIH M01 RR02602 (University of Kentucky General Clinical Research Center). We thank Sherry Chandler Williams, ELS, for manuscript preparation and editing.

Keywords

Arundic acid
Astrocyte
Cerebral ischemia
S-100 protein

ASJC Scopus subject areas

Neurology
Clinical Neurology

Access to Document

10.1016/j.jns.2006.09.002

Cite this

@article{4d9b84951a894945874b2f1550faa71d,

title = "Effect of arundic acid on serum S-100β in ischemic stroke",

abstract = "We prospectively examined the effect of arundic acid (AA; ONO-2506) on S-100β, an astrocyte-derived protein, in a phase I acute stroke study. Subjects with acute ischemic stroke were randomized to daily infusion of AA or placebo for 7 days. Serum S-100β levels were assayed pre-infusion on Days 1-7 and post-infusion on Days 1, 3, and 7, and correlated with National Institutes of Health Stroke Scale (NIHSS). Samples were obtained from 86 subjects (46 AA, 40 placebo). Increase in S-100β protein level from baseline was less in the AA cohort than in the placebo cohort at 7 (p = 0.0471; t-test) and 12 (p = 0.0095)-hours post-infusion on Day 3. Baseline NIHSS correlated with maximal S-100β levels between Days 1 and 3 in the AA (r = 0.51; p = 0.0003) and placebo (r = 0.41; p = 0.0084) cohorts and in the pooled aggregate (n = 86; r = 0.46; p < 0.0001). The same correlations were observed between Day 10 NIHSS and Day 1-3 maximum serum S-100β levels. Treatment with AA was associated with lower serum levels of S-100β after acute ischemic stroke. Our results showing correlation between S-100β and NIHSS indicate that this protein is a clinically relevant marker of neurological deficit in acute stroke.",

keywords = "Arundic acid, Astrocyte, Cerebral ischemia, S-100 protein",

author = "Pettigrew, {L. Creed} and Kasner, {Scott E.} and Mark Gorman and Atkinson, {Richard P.} and Yosuke Funakoshi and Hideyasu Ishibashi",

note = "Funding Information: Financial support for this work was provided by Ono Pharma USA Inc., of Lawrenceville, NJ, as a grant awarded to each participating center and by NIH M01 RR02602 (University of Kentucky General Clinical Research Center). We thank Sherry Chandler Williams, ELS, for manuscript preparation and editing. ",

year = "2006",

month = dec,

day = "21",

doi = "10.1016/j.jns.2006.09.002",

language = "English",

volume = "251",

pages = "57--61",

number = "1-2",

}

TY - JOUR

T1 - Effect of arundic acid on serum S-100β in ischemic stroke

AU - Pettigrew, L. Creed

AU - Kasner, Scott E.

AU - Gorman, Mark

AU - Atkinson, Richard P.

AU - Funakoshi, Yosuke

AU - Ishibashi, Hideyasu

N1 - Funding Information: Financial support for this work was provided by Ono Pharma USA Inc., of Lawrenceville, NJ, as a grant awarded to each participating center and by NIH M01 RR02602 (University of Kentucky General Clinical Research Center). We thank Sherry Chandler Williams, ELS, for manuscript preparation and editing.

PY - 2006/12/21

Y1 - 2006/12/21

N2 - We prospectively examined the effect of arundic acid (AA; ONO-2506) on S-100β, an astrocyte-derived protein, in a phase I acute stroke study. Subjects with acute ischemic stroke were randomized to daily infusion of AA or placebo for 7 days. Serum S-100β levels were assayed pre-infusion on Days 1-7 and post-infusion on Days 1, 3, and 7, and correlated with National Institutes of Health Stroke Scale (NIHSS). Samples were obtained from 86 subjects (46 AA, 40 placebo). Increase in S-100β protein level from baseline was less in the AA cohort than in the placebo cohort at 7 (p = 0.0471; t-test) and 12 (p = 0.0095)-hours post-infusion on Day 3. Baseline NIHSS correlated with maximal S-100β levels between Days 1 and 3 in the AA (r = 0.51; p = 0.0003) and placebo (r = 0.41; p = 0.0084) cohorts and in the pooled aggregate (n = 86; r = 0.46; p < 0.0001). The same correlations were observed between Day 10 NIHSS and Day 1-3 maximum serum S-100β levels. Treatment with AA was associated with lower serum levels of S-100β after acute ischemic stroke. Our results showing correlation between S-100β and NIHSS indicate that this protein is a clinically relevant marker of neurological deficit in acute stroke.

AB - We prospectively examined the effect of arundic acid (AA; ONO-2506) on S-100β, an astrocyte-derived protein, in a phase I acute stroke study. Subjects with acute ischemic stroke were randomized to daily infusion of AA or placebo for 7 days. Serum S-100β levels were assayed pre-infusion on Days 1-7 and post-infusion on Days 1, 3, and 7, and correlated with National Institutes of Health Stroke Scale (NIHSS). Samples were obtained from 86 subjects (46 AA, 40 placebo). Increase in S-100β protein level from baseline was less in the AA cohort than in the placebo cohort at 7 (p = 0.0471; t-test) and 12 (p = 0.0095)-hours post-infusion on Day 3. Baseline NIHSS correlated with maximal S-100β levels between Days 1 and 3 in the AA (r = 0.51; p = 0.0003) and placebo (r = 0.41; p = 0.0084) cohorts and in the pooled aggregate (n = 86; r = 0.46; p < 0.0001). The same correlations were observed between Day 10 NIHSS and Day 1-3 maximum serum S-100β levels. Treatment with AA was associated with lower serum levels of S-100β after acute ischemic stroke. Our results showing correlation between S-100β and NIHSS indicate that this protein is a clinically relevant marker of neurological deficit in acute stroke.

KW - Arundic acid

KW - Astrocyte

KW - Cerebral ischemia

KW - S-100 protein

UR - http://www.scopus.com/inward/record.url?scp=33751220170&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33751220170&partnerID=8YFLogxK

U2 - 10.1016/j.jns.2006.09.002

DO - 10.1016/j.jns.2006.09.002

M3 - Article

C2 - 17092520

AN - SCOPUS:33751220170

SN - 0022-510X

VL - 251

SP - 57

EP - 61

JO - Journal of the Neurological Sciences

JF - Journal of the Neurological Sciences

IS - 1-2

ER -

Effect of arundic acid on serum S-100β in ischemic stroke

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this